ACLARIS THERAPEUTICS, INC.00461U105US00461U105106/04/2026To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying the proxy card.SECTION 14A SAY-ON-PAY VOTESISSUER93450000FOR9345000FOR AKERO THERAPEUTICS, INC00973Y108US00973Y108212/02/2025To approve, on an advisory, non-binding basis, the payment of certain compensation that may be paid or become payable by Akero to its named executive officers in connection with the Merger.SECTION 14A SAY-ON-PAY VOTESISSUER23327450FOR2332745FOR ALIGOS THERAPEUTICS, INC.01626L204US01626L204306/25/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this notice pursuant to the compensation disclosure rules of the Securities and Exchange Commission (''Say-on-Pay''); andSECTION 14A SAY-ON-PAY VOTESISSUER4441100FOR444110FOR ALIGOS THERAPEUTICS, INC.01626L204US01626L204306/25/2026To approve, on a non-binding, advisory basis, whether a Say-on-Pay vote should occur every one year, every two years or every three years.SECTION 14A SAY-ON-PAY VOTESISSUER44411001 YEAR444110FOR ALKERMES PLCG01767105IE00B56GVS1505/20/2026To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER35903230FOR3590323FOR ANI PHARMACEUTICALS, INC.00182C103US00182C103605/21/2026To approve the compensation of the Company's named executive officers, on a non-binding, advisory basis.SECTION 14A SAY-ON-PAY VOTESISSUER6000000FOR600000FOR ANI PHARMACEUTICALS, INC.00182C103US00182C103605/21/2026To approve the frequency of future advisory votes to approve the compensation of the Company's named executive officers, on a non-binding basis.SECTION 14A SAY-ON-PAY VOTESISSUER60000001 YEAR600000FOR AXSOME THERAPEUTICS, INC.05464T104US05464T104306/05/2026To approve, by non-binding advisory vote, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1595290FOR159529FOR BEAM THERAPEUTICS INC.07373V105US07373V105206/03/2026Approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER10000000FOR1000000FOR BRIDGEBIO PHARMA, INC.10806X102US10806X102806/22/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER334850FOR33485FOR BRIDGEBIO PHARMA, INC.10806X102US10806X102806/22/2026To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3348501 YEAR33485FOR CELLDEX THERAPEUTICS, INC.15117B202US15117B202506/25/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER10308880FOR1030888FOR COGENT BIOSCIENCES, INC.19240Q201US19240Q201206/09/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER12000000FOR1200000FOR COMPASS PATHWAYS PLC20451W101US20451W101805/27/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers for the year ended 31 December 2025SECTION 14A SAY-ON-PAY VOTESISSUER121614960FOR12161496FOR CORMEDIX INC.21900C308US21900C308806/23/2026To approve on a non-binding advisory basis the compensation of our named executive officers for 2025.SECTION 14A SAY-ON-PAY VOTESISSUER49773520FOR4977352FOR CORVUS PHARMACEUTICALS, INC.221015100US221015100506/11/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER24877750FOR2487775FOR CRESCENT BIOPHARMA, INC.G2545C104KYG2545C104206/02/2026To approve, on a non-binding, advisory basis, the compensation of Crescent Biopharma, Inc.'s named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4403420FOR440342FOR CRESCENT BIOPHARMA, INC.G2545C104KYG2545C104206/02/2026To vote, on a non-binding advisory basis, on the frequency of future advisory votes to approve compensation for Crescent Biopharma, Inc.'s named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER44034201 YEAR440342FOR DYNE THERAPEUTICS, INC.26818M108US26818M108006/05/2026To vote, on an advisory basis, to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER19485390FOR1948539FOR ENANTA PHARMACEUTICALS, INC.29251M106US29251M106203/11/2026To approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER19568670FOR1956867FOR GENMAB A S372303206US372303206203/19/2026Advisory vote on the Compensation ReportSECTION 14A SAY-ON-PAY VOTESISSUER16140FOR1614FOR GENMAB A/SK3967W102DK001027220203/19/2026IT IS PROPOSED TO APPROVE THE 2025 COMPENSATION REPORTSECTION 14A SAY-ON-PAY VOTESISSUER3805611709FOR380561FOR GERON CORPORATION374163103US374163103605/20/2026To approve, on an advisory basis, the compensation of our Named Executive Officers, as disclosed in our Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER308869190FOR30886919FOR GUARDANT HEALTH, INC.40131M109US40131M109906/17/2026Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER29581220FOR2958122FOR GUARDANT HEALTH, INC.40131M109US40131M109906/17/2026Non-binding advisory vote on the frequency of stockholder advisory votes regarding compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER295812201 YEAR2958122FOR H. LUNDBECK A/SK4406L137DK006180477003/18/2026PRESENTATION OF AND ADVISORY VOTE ON THE REMUNERATION REPORTSECTION 14A SAY-ON-PAY VOTESISSUER0771264 IMMUNOCORE HOLDINGS PLC45258D105US45258D105405/27/2026To approve, on advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER19218730FOR1921873FOR IMMUNOVANT, INC.45258J102US45258J102508/27/2025To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER95000000FOR9500000FOR INVENTIVA S.A.46124U107US46124U107906/30/2026Final approval of the fixed and variable compensation paid or awarded to Mr. Mark Pruzanski in his capacity as Chairman of the Board of Directors for the financial year ended December 31, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER23512780FOR2351278FOR INVENTIVA S.A.46124U107US46124U107906/30/2026Final approval of the fixed and variable compensation paid or awarded to Mr. Frédéric Cren in his capacity as Chief Executive Officer until September 30, 2025, for the financial year ended December 31, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER23512780FOR2351278FOR INVENTIVA S.A.46124U107US46124U107906/30/2026Final approval of the fixed and variable compensation paid or awarded to Mr. Andrew Obenshain in his capacity as Chief Executive Officer from October 1, 2025, for the financial year ended December 31, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER23512780FOR2351278FOR INVENTIVA S.A.46124U107US46124U107906/30/2026Final approval of the fixed and variable compensation paid or awarded to Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer until June 30, 2025, for the financial year ended December 31, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER23512780FOR2351278FOR INVENTIVA S.A.46124U107US46124U107906/30/2026Approval of the information on corporate officers' compensation included in the corporate governance report and referred to in Article L.22-10-9 I. of the French Commercial Code.SECTION 14A SAY-ON-PAY VOTESISSUER23512780FOR2351278FOR INVENTIVA SAF5R343107FR001323301206/30/2026FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. MARK PRUZANSKI IN HIS CAPACITY AS CHAIRMAN OF THE BOARD OF DIRECTORS FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025SECTION 14A SAY-ON-PAY VOTESISSUER19768200FOR1976820FOR INVENTIVA SAF5R343107FR001323301206/30/2026FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. FREDERIC CREN IN HIS CAPACITY AS CHIEF EXECUTIVE OFFICER UNTIL SEPTEMBER 30, 2025 FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025SECTION 14A SAY-ON-PAY VOTESISSUER19768200FOR1976820FOR INVENTIVA SAF5R343107FR001323301206/30/2026FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. ANDREW OBENSHAIN IN HIS CAPACITY AS CHIEF EXECUTIVE OFFICER FROM OCTOBER 1ST, 2025 FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025SECTION 14A SAY-ON-PAY VOTESISSUER19768200FOR1976820FOR INVENTIVA SAF5R343107FR001323301206/30/2026FINAL APPROVAL OF THE FIXED AND VARIABLE COMPENSATION PAID OR AWARDED TO MR. PIERRE BROQUA IN HIS CAPACITY AS DEPUTY CHIEF EXECUTIVE OFFICER UNTIL JUNE 30, 2025 FOR THE FINANCIAL YEAR ENDED DECEMBER 31ST, 2025SECTION 14A SAY-ON-PAY VOTESISSUER19768200FOR1976820FOR IONIS PHARMACEUTICALS, INC.462222100US462222100406/04/2026To make an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER17484580FOR1748458FOR JANUX THERAPEUTICS, INC.47103J105US47103J105106/11/2026To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER4192480FOR419248FOR KURA ONCOLOGY, INC.50127T109US50127T109706/04/2026Approval, on an advisory basis, of the compensation of our named executive officers ("Say-on-Pay"), as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER18858900FOR1885890FOR KURA ONCOLOGY, INC.50127T109US50127T109706/04/2026Indication, on an advisory basis, of the preferred frequency of holding future Say-on-Pay votes on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER188589001 YEAR1885890FOR LARIMAR THERAPEUTICS, INC.517125100US517125100305/19/2026Approval, on an Advisory Basis, of the Compensation of our Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER13450920FOR1345092FOR LARIMAR THERAPEUTICS, INC.517125100US517125100305/19/2026Approval, on an Advisory Basis, of the Preferred Frequency of Future Advisory Votes on the Compensation of our Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER134509201 YEAR1345092FOR MOONLAKE IMMUNOTHERAPEUTICS61559X104KY61559X104506/04/2026Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER64088630FOR6408863FOR NURIX THERAPEUTICS, INC.67080M103US67080M103605/15/2026To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER51983030FOR5198303FOR NUVALENT, INC.670703107US670703107506/16/2026To approve, on an advisory basis, the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER15789090FOR1578909FOR OCULAR THERAPEUTIX, INC.67576A100US67576A100706/10/2026To approve an advisory vote on named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER140024810FOR14002481FOR OCULAR THERAPEUTIX, INC.67576A100US67576A100706/10/2026To approve, on a non-binding, advisory basis, the frequency of future advisory votes to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1400248101 YEAR14002481FOR ORUKA THERAPEUTICS, INC.687604108US687604108706/02/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER20192030FOR2019203FOR PERSONALIS, INC.71535D106US71535D106305/12/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER9038270FOR903827FOR SOLID BIOSCIENCES INC.83422E204US83422E204606/10/2026The approval of an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER35650620FOR3565062FOR STRUCTURE THERAPEUTICS, INC.86366E106US86366E106406/17/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER40798480FOR4079848FOR TANGO THERAPEUTICS, INC.87583X109US87583X109006/04/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER27500000FOR2750000FOR TARSUS PHARMACEUTICALS, INC.87650L103US87650L103506/25/2026To hold an advisory vote to approve, on a non-binding basis, our named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER35576780FOR3557678FOR UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Advisory resolution to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1334160FOR133416FOR VALNEVA SEF9635C101FR000405685106/25/2026APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL COMPONENTS MAKING UP THE TOTAL COMPENSATION AND BENEFITS OF ANY KIND PAID DURING, OR GRANTED IN RESPECT OF THE FISCAL YEAR ENDED DECEMBER 31, 2025, TO MS. ANNE-MARIE GRAFFIN, CHAIR OF THE BOARD OF DIRECTORSSECTION 14A SAY-ON-PAY VOTESISSUER02901471 VALNEVA SEF9635C101FR000405685106/25/2026APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL COMPONENTS MAKING UP THE TOTAL COMPENSATION AND BENEFITS OF ANY KIND PAID DURING, OR GRANTED IN RESPECT OF THE FISCAL YEAR ENDED DECEMBER 31, 2025, TO MR. THOMAS LINGELBACH, CEOSECTION 14A SAY-ON-PAY VOTESISSUER02901471 VALNEVA SEF9635C101FR000405685106/25/2026APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL COMPONENTS MAKING UP THE TOTAL COMPENSATION AND BENEFITS OF ANY KIND PAID DURING, OR GRANTED IN RESPECT OF THE FISCAL YEAR ENDED DECEMBER 31, 2025, TO MR. JUAN CARLOS JARAMILLO, IN HIS CAPACITY AS ASSOCIATE MANAGING OFFICERSECTION 14A SAY-ON-PAY VOTESISSUER02901471 VALNEVA SEF9635C101FR000405685106/25/2026APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL COMPONENTS MAKING UP THE TOTAL COMPENSATION AND BENEFITS OF ANY KIND PAID DURING, OR GRANTED IN RESPECT OF THE FISCAL YEAR ENDED DECEMBER 31, 2025, TO MR. PETER BUHLER, IN HIS CAPACITY AS ASSOCIATE MANAGING OFFICERSECTION 14A SAY-ON-PAY VOTESISSUER02901471 VALNEVA SEF9635C101FR000405685106/25/2026APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL COMPONENTS MAKING UP THE TOTAL COMPENSATION AND BENEFITS OF ANY KIND PAID DURING, OR GRANTED IN RESPECT OF THE FISCAL YEAR ENDED DECEMBER 31, 2025, TO MS. DIPAL PATEL, IN HER CAPACITY AS ASSOCIATE MANAGING OFFICERSECTION 14A SAY-ON-PAY VOTESISSUER02901471 VALNEVA SEF9635C101FR000405685106/25/2026APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL COMPONENTS MAKING UP THE TOTAL COMPENSATION AND BENEFITS OF ANY KIND PAID DURING, OR GRANTED IN RESPECT OF THE FISCAL YEAR ENDED DECEMBER 31, 2025, TO MR. FRANCK GRIMAUD, IN HIS CAPACITY AS ASSOCIATE MANAGING OFFICERSECTION 14A SAY-ON-PAY VOTESISSUER02901471 VAXCYTE, INC.92243G108US92243G108506/15/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER40802480FOR4080248FOR VERA THERAPEUTICS, INC.92337R101US92337R101405/21/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER26926170FOR2692617FOR VERASTEM, INC.92337C203US92337C203505/21/2026To approve an advisory vote on the compensation of the named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER57408500FOR5740850FOR VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/02/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER18922810FOR1892281FOR VIRIDIAN THERAPEUTICS, INC.92790C104US92790C104506/02/2026To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER189228101 YEAR1892281FOR X4 PHARMACEUTICALS, INC.98420X202US98420X202705/11/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER44363100FOR4436310FOR